[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626723":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":26,"locations":10,"responsibleParty":32,"collaborators":10,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":10,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":10,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":60,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":10},{"fullName":5,"class":6},"Bursa City Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Familial Mediterranean Fever Patients",null,"Patients aged 18-65 years diagnosed with Familial Mediterranean Fever according to Tel-Hashomer criteria. Participants will undergo a single non-invasive skin autofluorescence measurement for assessment of advanced glycation end products (AGE). Routine laboratory parameters will be used to calculate the CALLY index. No intervention or treatment assignment will be performed.",[13],"Device: Skin Autofluorescence Measurement",{"label":15,"type":10,"description":16,"interventionNames":17},"Healthy Controls","Age- and sex-matched healthy volunteers without chronic inflammatory or metabolic disease. Participants will undergo a single non-invasive skin autofluorescence measurement for assessment of advanced glycation end products (AGE). No intervention or treatment assignment will be performed.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DEVICE","Skin Autofluorescence Measurement","Non-invasive measurement of advanced glycation end products (AGE) using skin autofluorescence technology. The assessment is performed once at baseline using a validated optical device applied to the volar side of the forearm. The procedure is painless, requires no blood sampling, and does not involve any therapeutic intervention or treatment assignment.",[9,15],[25],"AGE Reader",[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"altuğ güner","CONTACT","02249750000","altugguner555@gmail.com",{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Altuğ Güner","Principal Investigator","100626723","age-and-cally-index-in-familial-mediterranean-fever-100626723",false,"NCT07439341","AGE and CALLY Index in Familial Mediterranean Fever","Association Between Skin Autofluorescence-Measured Advanced Glycation End Products and the CALLY Index in Patients With Familial Mediterranean Fever: A Cross-Sectional Controlled Study","Inclusion Criteria:\n\nFor FMF Patients:\n\n* Age between 18 and 65 years\n* Diagnosis of Familial Mediterranean Fever according to Tel-Hashomer criteria\n* At least 6 months of clinical follow-up\n* Available routine laboratory data (CRP, albumin, lymphocyte count)\n* Not in an acute FMF attack at the time of assessment\n* Ability to provide written informed consent\n\nFor Healthy Controls:\n\n* Age between 18 and 65 years\n* No history of chronic inflammatory, autoimmune, metabolic, or renal disease\n* Ability to provide written informed consent\n\nExclusion Criteria :\n\n* Diagnosis of diabetes mellitus\n* Chronic kidney disease stage 3 or higher\n* Active infection\n* Malignancy within the past 5 years\n* Dermatologic condition affecting the forearm measurement site\n* Use of high-dose antioxidant or vitamin supplementation within the past 3 months\n* Any condition that, in the opinion of the investigators, may interfere with study participation",true,"ALL","18 Years","65 Years",{"count":48,"type":49},150,"ESTIMATED","OBSERVATIONAL","Familial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by recurrent inflammatory attacks and persistent low-grade inflammation. Even during attack-free periods, subclinical inflammation may continue and contribute to long-term complications.\n\nAdvanced glycation end products (AGEs) are molecules that accumulate under chronic inflammatory and oxidative stress conditions. AGEs can be measured non-invasively using skin autofluorescence (SAF). The C-reactive protein-albumin-lymphocyte (CALLY) index is a composite marker derived from routine laboratory parameters and reflects systemic inflammation and nutritional status.\n\nThis observational cross-sectional study aims to evaluate the association between skin autofluorescence-measured AGE levels and the CALLY index in patients with FMF. The study will also compare AGE levels between FMF patients and age- and sex-matched healthy controls.\n\nThe study does not involve any intervention, treatment assignment, or randomization. All laboratory parameters will be obtained from routine clinical evaluations, and AGE measurement will be performed using a non-invasive device.",[53],"Familial Mediterranean Fever",[55,56,57,58,59],"Advanced Glycation End Products","Skin Autofluorescence","CALLY Index","Amyloidosis","Inflammatory Biomarkers","NOT_YET_RECRUITING","2026-02-23",{"date":63,"type":64},"2026-02-27","ACTUAL",{"date":66,"type":49},"2026-02-01",{"date":68,"type":49},"2026-11-01",{"name":5,"class":6}]